Acorda Therapeutics Acquires 2 Pain Management Assets From NeurogesX

Anuja Vaidya - Print  |

Ardsley, N.Y.-based Acorda Therapeutics, a biotechnology company, announced that it has acquired two neuropathic pain management assets from NeurogesX in San Mateo, Calif., a specialty pharmaceutical company that develops non-opioid, pain management therapies.

The company acquired Qutenza, an FDA-approved pain patch for the management of neuropathic pain associated with postherpetic neuralgia. It also acquired NP-1998, a prescription strength capsaicin topical solution, which being assessed for the treatment of neuropathic pain and is ready for phase three of its trial.

More Articles on Pain Management:

Sussex Pain Relief Center Breaks Ground on New Location in Delaware
Florida's Lake County to Extend Pain Management Clinic Ban
Arizona Pain Specialists Opens New Location

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.